Serina Therapeutics, Inc. Price & Performance (SER)

Gain Therapeutics has reported a reduced net loss for 2024 and initiated dosing in its Phase 1b trial for GT-02287, targeting Parkinson’s disease. The company expects first trial analysis results by mid-2025 and plans to submit an IND to the FDA by year-end, reflecting ongoing clinical and financial progress.123

Plus Therapeutics’ stock has surged after the FDA granted orphan drug status to its radiotherapy for leptomeningeal metastases and conditionally accepted the brand name Reyobiq. The company’s experimental drug has shown improved survival in glioblastoma, fueling positive sentiment despite ongoing financial challenges typical in early-stage biotech.45

Serina Therapeutics has eliminated $11.2 million in subsidiary debt following the sale of UniverXome and is now debt-free entering 2025. The company is advancing its SER-252 candidate for advanced Parkinson’s disease and expanding its POZ Platform™ technology across several therapeutic areas, signaling renewed strategic focus.67